EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers

Yi Rao iD, Zachary Samuels, Lukas M Carter iD, Sebastien Monette iD, Sandeep Surendra Panikar iD, Patricia M R Pereira, Jason S Lewis iD

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2220413120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Yi Rao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065. Hauptthemen laut MEDLINE: Stomach Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) is overexpressed in various cancer types. HER2-targeting trastuzumab plus chemotherapy is used as first-line therapy for HER2-positive recurrent or primary metastatic gastric cancer, but intrinsic and acquired trastuzumab resistance inevitably develop over time. To overcome gastric cancer resistance to HER2-targeted therapies, we have conjugated trastuzumab with a beta-emitting therapeutic isotope, lutetium-177, to deliver radiation locally to gastric tumors with minimal toxicity. Because trastuzumab-based targeted radioligand therapy (RLT) requires only the extramembrane domain binding of membrane-bound HER2 receptors, HER2-targeting RLT can bypass any resistance mechanisms that occur downstream of HER2 binding. Leveraging our previous discoveries that statins, a class of cholesterol-lowering drugs, can enhance the cell surface-bound HER2 to achieve effective drug delivery in tumors, we proposed that the combination of statins and [ 177 Lu]Lu-trastuzumab-based RLT can enhance the therapeutic efficacy of HER2-targeted RLT in drug-resistant gastric cancers. We demonstrate that lovastatin elevates cell surface HER2 levels and increases the tumor-absorbed radiation dose of [ 177 Lu]Lu-DOTA-trastuzumab. Furthermore, lovastatin-modulated [ 177 Lu]Lu-DOTA-trastuzumab RLT durably inhibits tumor growth and prolongs overall survival in mice bearing NCI-N87 gastric tumors and HER2-positive patient-derived xenografts (PDXs) of known clinical resistance to trastuzumab therapy. Statins also exhibit a radioprotective effect, reducing radiotoxicity in a mice cohort given the combination of statins and [ 177 Lu]Lu-DOTA-trastuzumab. Since statins are commonly prescribed to patients, our results strongly support the feasibility of clinical studies that combine lovastatin with HER2-targeted RLT in HER2-postive patients and trastuzumab-resistant HER2-positive patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsHumansAnimalsMicePharmaceutical PreparationsErb-b2 Receptor Tyrosine KinasesTrastuzumabLovastatinCell Line, Tumor

Stichwörter der Autor:innen

human epidermal growth factor receptor 2 (HER2)radioligand therapystatinstrastuzumabtrastuzumab-resistant cancer

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsPharmaceutical PreparationsErb-b2 Receptor Tyrosine KinasesTrastuzumabLovastatin

Autor:innen und Institutionen

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY 10065.
  • Department of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.
  • Department of Pharmacology, Weill Cornell Medicine, New York, NY 10021.
  • Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065.

ORCID-Profile: Yi Rao, Lukas M Carter, Sebastien Monette, Sandeep Surendra Panikar, Jason S Lewis

Förderung

  • NCI NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Rao, Y., Samuels, Z., Carter, L. M., Monette, S., Panikar, S. S., Pereira, P. M. R., & Lewis, J. S. (2023). Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2220413120

Vancouver

Rao Y, Samuels Z, Carter LM, Monette S, Panikar SS, Pereira PMR, et al. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2220413120

BibTeX
@article{Rao2023,
  author = {Rao, Yi and Samuels, Zachary and Carter, Lukas M and Monette, Sebastien and Panikar, Sandeep Surendra and Pereira, Patricia M R and Lewis, Jason S},
  title = {Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2220413120}
}
Kostenlos starten →